The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
作者信息
Oortgiesen Berdien E, Azad Roshna, Hemmelder Marc H, Kibbelaar Robby E, Veeger Nic J G M, de Vries Joost C, van Roon Eric N, Hoogendoorn Mels
机构信息
Department of Clinical Pharmacy and Pharmacology, Medical Center Leeuwarden, the Netherlands
Department of Clinical Pharmacy and Pharmacology, Medical Center Leeuwarden, the Netherlands.
出版信息
Haematologica. 2018 Jul;103(7):e311-e314. doi: 10.3324/haematol.2017.184754. Epub 2018 Mar 15.
Abstract
摘要
相似文献
1
The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
Haematologica. 2018 Jul;103(7):e311-e314. doi: 10.3324/haematol.2017.184754. Epub 2018 Mar 15.
2
A population-based study of the impact of dialysis on mortality in multiple myeloma.
Br J Haematol. 2018 Feb;180(4):588-591. doi: 10.1111/bjh.14394. Epub 2016 Oct 21.
3
Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):e395-e398. doi: 10.1016/j.clml.2020.03.014. Epub 2020 Apr 7.
4
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.
Haematologica. 2018 Jun;103(6):e277-e278. doi: 10.3324/haematol.2018.191122. Epub 2018 Apr 5.
5
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.
Blood Cancer J. 2016 Mar 25;6(3):e409. doi: 10.1038/bcj.2016.17.
6
Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.
Medicine (Baltimore). 2016 Nov;95(46):e5202. doi: 10.1097/MD.0000000000005202.
7
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.
8
Outcome of patients with multiple myeloma and renal failure on novel regimens.
Saudi J Kidney Dis Transpl. 2016 Mar;27(2):335-40. doi: 10.4103/1319-2442.178557.
9
Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
J Clin Lab Anal. 2019 Jun;33(5):e22888. doi: 10.1002/jcla.22888. Epub 2019 Apr 19.
10
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
Zhonghua Nei Ke Za Zhi. 2016 Oct 1;55(10):764-768. doi: 10.3760/cma.j.issn.0578-1426.2016.10.008.
引用本文的文献
1
Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study.
Ther Adv Med Oncol. 2025 Aug 21;17:17588359251357682. doi: 10.1177/17588359251357682. eCollection 2025.
2
Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China.
Am J Cancer Res. 2023 Apr 15;13(4):1571-1581. eCollection 2023.
3
Activation of ER Stress-Dependent miR-216b Has a Critical Role in Ethanol-Extract-Induced Apoptosis in U266 and U937 Cells.
Int J Mol Sci. 2018 Apr 19;19(4):1240. doi: 10.3390/ijms19041240.
本文引用的文献
1
Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.
Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1277385. Epub 2017 Feb 14.
2
A population-based study of the impact of dialysis on mortality in multiple myeloma.
Br J Haematol. 2018 Feb;180(4):588-591. doi: 10.1111/bjh.14394. Epub 2016 Oct 21.
3
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.
Blood Cancer J. 2016 Mar 25;6(3):e409. doi: 10.1038/bcj.2016.17.
4
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.
5
Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):431-41. doi: 10.2215/CJN.06290615. Epub 2016 Jan 4.
6
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5.
7
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
J Clin Oncol. 2010 Nov 20;28(33):4976-84. doi: 10.1200/JCO.2010.30.8791. Epub 2010 Oct 18.
8
Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study.
Nephrol Dial Transplant. 2010 Apr;25(4):1200-6. doi: 10.1093/ndt/gfp679. Epub 2009 Dec 27.
9
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059.
10
Pathogenesis and treatment of renal failure in multiple myeloma.
Leukemia. 2008 Aug;22(8):1485-93. doi: 10.1038/leu.2008.131. Epub 2008 Jun 5.
Zotero 插件